Peptide Sciences Alternatives: A Verification-First Framework | Artemis Labs
Peptide Sciences Alternatives: A Verification-First Comparison Framework
Published August 21, 2026 · Artemis Labs
Peptide Sciences alternatives — Peptide Sciences announced its closure on March 6, 2026 and halted all order processing. A successor should be judged on six verifiable criteria — third-party HPLC purity and MS identity testing, a Certificate of Analysis with every order, citation density, honest counter-evidence, no administration supplies, and published policies — not on the scale the closed vendor once had.
Key findings
- Peptide Sciences closed on March 6, 2026, halting all order processing. Industry traffic estimates placed the company in a roughly $7.4-million-per-month revenue class — the largest US research-peptide vendor at the time.
- Scale did not protect buyers. The company’s own closure notice states that any further sales under the Peptide Sciences brand are fraudulent, and unaffiliated sites reusing the branding have appeared since.
- Verification transfers; scale does not. Third-party HPLC and MS testing, per-order COAs, and cited references can be checked at any vendor — a yardstick a researcher carries to whichever supplier comes next.
What researchers lost when Peptide Sciences closed
Peptide Sciences announced its closure on March 6, 2026, halted all order processing, and took its site offline shortly afterward. Industry traffic estimates — estimates, not audited figures — placed the company in a roughly $7.4-million-per-month revenue class, which made it the largest US research-peptide vendor at the time of the announcement. The loss for researchers was practical: a deep catalog, a familiar ordering routine, and a supplier relationship built over years ended in a single notice.
Peptide Sciences gave no detailed explanation for the decision. Industry coverage placed the closure against a wider backdrop — FDA enforcement activity across 2024–2026, GLP-1-related litigation pressure, and import restrictions — but those are context, not a stated cause. The dated account of the event, including the company’s own statement about its brand, is in our companion explainer on the Peptide Sciences shutdown and successor checklist.
Why scale is the wrong yardstick for a successor
Scale is the first thing a displaced buyer looks for and the least informative thing that can be measured. A vendor’s size says something about marketing reach and logistics; it says nothing about whether the vial that arrives matches the label. The recent record makes the point bluntly: the FDA’s December 2024 and March 2026 warning-letter batches named eleven entities of widely varying size, and the closures of 2025–2026 took down some of the largest names in the market. The full chronology is on our peptide vendor closures 2025-2026 hub.
Verification, unlike scale, transfers. A researcher who knows what a defensible Certificate of Analysis looks like, and what a well-cited product page looks like, can evaluate any vendor — new or established, large or small — with the same yardstick. That is the framework below.
Six criteria any vendor can be measured against
Each criterion below is checkable from public information or from a single order. None of them depends on a vendor’s marketing.
- Third-party HPLC purity and MS identity testing. Analysis performed outside the vendor’s own walls, covering both what the material is (mass spectrometry) and how pure it is (HPLC). A vendor that cannot say who tests its material has not answered the first question.
- A Certificate of Analysis with every order. Not a sample COA on a marketing page — a document that travels with the material shipped. Our guide to reading a Certificate of Analysis covers what the document should contain and how to read the traces.
- Citation density. Product-page claims that trace to PubMed or DOI links, with a references section a reader can actually follow. Claims without citations are marketing; claims with citations are checkable.
- Honest counter-evidence. A vendor willing to surface published findings that cut against a compound’s popularity is showing its evidentiary standard in public. Silence on negative findings is a choice.
- No administration supplies. FDA’s March 2026 warning letters cite administration supplies offered in the same cart as evidence that products were intended as drugs for human use. A research vendor has no reason to sell them.
- Published policies. Shipping, refund, privacy, and research-use terms in writing, findable before purchase — not discovered by email after something goes wrong.
The long-form version of this framework, with worked examples, is in our supplier-evaluation checklist for research-peptide vendors.
How Artemis Labs measures against each criterion
Artemis Labs meets the framework as follows, stated plainly and without ranking anyone else. Peptides are third-party tested — HPLC for purity, mass spectrometry for identity — and a Certificate of Analysis is included with every order. Product pages carry roughly 500 PubMed and DOI citations across the catalog, with a References section on every product page. Counter-evidence is surfaced: the Sun 2025 thymosin-beta-4 finding, for example, appears on the relevant product page. Artemis Labs sells no administration supplies and publishes no dosing or administration content anywhere on the site. Shipping, refund, privacy, and research-use terms are published in full — the shipping policy gives the rates, the processing time and what happens to a lost parcel, rather than leaving them to be discovered by email.
One honest limit belongs in the same paragraph as the claims: Artemis Labs does not yet operate a public lot-lookup portal — the Certificate of Analysis arrives with the order itself. Every compound in the Artemis Labs catalog is supplied for laboratory research use only.
Watch for sites trading on the Peptide Sciences name
Peptide Sciences stated in its closure notice that any further sales under its brand are fraudulent. Unaffiliated sites reusing the Peptide Sciences branding have appeared since the shutdown, which changes the buyer’s first question from “is this vendor good” to “is this vendor real.” A site presenting itself as Peptide Sciences today is, by the company’s own statement, not Peptide Sciences. Identification patterns and a step-by-step evaluation sequence are in the successor checklist.
Frequently asked questions
Is there a direct replacement for Peptide Sciences?
No single vendor replaces Peptide Sciences’ scale, and scale was never the meaningful measure. The workable approach is to hold candidate vendors — Artemis Labs included — against verifiable criteria: third-party testing, per-order COAs, cited claims, counter-evidence disclosure, no administration supplies, and published policies.
What should a researcher check first at an alternative vendor?
Testing documentation comes first: who performs the HPLC and MS analysis, and whether a Certificate of Analysis accompanies every order or appears only as a marketing sample. The COA reading guide shows what a complete document looks like.
Does Artemis Labs sell administration supplies?
No — Artemis Labs sells no administration supplies and publishes no dosing or administration content anywhere. FDA’s March 2026 letters cite administration supplies in the same cart as evidence of intended human use, which is why the framework above lists their absence as a criterion, not a detail.
References
- Peptides Explorer — “Peptide Sciences Shut Down.” peptidesexplorer.com/blog/peptide-sciences-shut-down
- BioStrata Research — “Did Peptide Sciences Shut Down?” biostrataresearch.com
- US FDA — Warning Letters database (December 10, 2024 and March 31, 2026 research-peptide batches). fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters
